KYMERA THERAPEUTICS INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 187
- Market Cap
- $3.1B
- Website
- http://www.kymeratx.com
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
- Conditions
- Healthy Participants Study
- Interventions
- Drug: KT-621Drug: Placebo
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06673667
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
- Conditions
- Acute Lymphocytic LeukemiaMyeloid MalignanciesLymphomasAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05775406
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
- Conditions
- Diffuse Large B Cell LymphomaDLBCLMYD88 Gene MutationNon Hodgkin Lymphoma
- Interventions
- Drug: KT-413
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05233033
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, D.C., District of Columbia, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
- Conditions
- Non Hodgkin Lymphoma (NHL)T-cell Prolymphocytic Leukemia (T-PLL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)Large Granular Lymphocytic Leukemia (LGL-L)Solid Tumors
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05225584
- Locations
- 🇺🇸
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
- Conditions
- Healthy VolunteerAtopic DermatitisHidradenitis Suppurativa
- Interventions
- Drug: KT-474/PlaceboDrug: KT-474
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT04772885
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Southwest Skin Specialists 32nd St, Phoenix, Arizona, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis
- Conditions
- Dermatitis, AtopicHidradenitis Suppurativa
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Kymera Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04440410
- Locations
- 🇨🇦
York Dermatology Clinic and Research Centre, Richmond Hill, Ontario, Canada